Manta Biosystems, Inc.

Manta Biosystems, Inc. , based in the US, specializes in advanced molecular detection systems to enhance testing efficiency across various industries, focusing on microbial detection technology. Founded in 2025 and headquartered in Beverly, US, Manta Biosystems, Inc. develops innovative solutions for rapid microbial detection.

The company raised USD 2. 5 mn in Seed funding on May 13, 2025, aimed at developing new testing platforms and techniques. The company has engaged in a total of 1 deal to date, enhancing its operational capabilities and market reach. Manta Biosystems specializes in the development of advanced molecular detection systems, with a primary focus on its flagship product, the MantaVision System.

This fully automated technology employs real-time PCR chemistry to enable rapid and accurate detection of problematic microbes at the point-of-need, significantly enhancing testing efficiency across various sectors. The MantaVision System serves diverse industries, including biopharmaceutical manufacturing, veterinary diagnostics, human clinical diagnostics, and food safety, effectively addressing the critical need for timely microbial contamination testing. It targets end-users such as laboratories, healthcare providers, and manufacturers who require reliable microbial monitoring solutions. Manta Biosystems' products are available in North America, Europe, and Asia, catering to a global customer base that demands stringent microbial testing capabilities.

Manta Biosystems' revenue is primarily derived from transactions involving the sale of its MantaVision System and associated services. The company engages in B2B transactions, partnering with various industries requiring rapid microbial detection solutions. Customers typically acquire the MantaVision System through direct sales agreements, which may include optional service contracts for ongoing maintenance and support. The revenue model includes one-time purchases for the equipment and recurring revenue from consumables and service agreements.

As a technology-driven firm, Manta Biosystems aims to establish strategic partnerships to expand its market reach and enhance product adoption across its targeted industries. In May 2025, Manta Biosystems, Inc. raised USD 2. 5 mn in Seed funding from unspecified investors.

The company will utilize this funding to innovate and develop new testing platforms and techniques. Manta Biosystems plans to introduce new products aimed at improving microbial detection capabilities and expand its market presence in specific regions. By enhancing their technological offerings and market penetration strategies, Manta aims to solidify its position in the global market for microbial detection.